'''Licostinel''' ([[International Nonproprietary Name|INN]]) (code name '''ACEA-1021''') is a [[competitive antagonist|competitive]], [[silent antagonist]] of the [[glycine site]] of the [[NMDA receptor]] (K<sub>b</sub> = 5 nM).<ref name="GillPulido2007">{{cite book|author1=Santokh Gill|author2=Olga Pulido|title=Glutamate Receptors in Peripheral Tissue: Excitatory Transmission Outside the CNS|url=https://books.google.com/books?id=wcjiZ58mypIC&pg=PA36|date=31 January 2007|publisher=Springer Science & Business Media|isbn=978-0-306-48644-9|pages=36–}}</ref><ref name="GusevSkvortsova2003">{{cite book|author1=Eugene I. Gusev|author2=Veronika I. Skvortsova|title=Brain Ischemia|url=https://books.google.com/books?id=TLla0xisFkoC&pg=PA249|date=30 April 2003|publisher=Springer Science & Business Media|isbn=978-0-306-47694-5|pages=249–}}</ref><ref name="pmid8643094">{{cite journal | vauthors = Wilding TJ, Huettner JE | title = Antagonist pharmacology of kainate- and alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid-preferring receptors | journal = Mol. Pharmacol. | volume = 49 | issue = 3 | pages = 540–6 | year = 1996 | pmid = 8643094 | doi = | url = http://molpharm.aspetjournals.org/cgi/pmidlookup?view=long&pmid=8643094}}</ref><ref name="pmid8643094"/> It was under investigation by Acea Pharmaceuticals as a [[neuroprotective agent]] for the treatment of [[cerebral ischemia]] associated with [[stroke]] and [[head injury|head injuries]] but was ultimately never marketed.<ref name="GillPulido2007" /><ref name="GusevSkvortsova2003" /><ref name="SirinathsinghjiHill2002">{{cite book|author1=Dalip J. S. Sirinathsinghji|author2=Ray G. Hill|title=Nmda Antagonists As Potential Analgesic Drugs|url=https://books.google.com/books?id=pIDGlb1ISCgC&pg=PA151|date=1 January 2002|publisher=Springer Science & Business Media|isbn=978-3-7643-6011-5|pages=151–}}</ref> In [[clinical trial]]s, licostinel did not produce [[phencyclidine]]-like [[psychotomimetic]] effects at the doses tested, though transient [[sedation]], [[dizziness]], and [[nausea]] were observed.<ref name="SirinathsinghjiHill2002"/><ref name="BountraMunglani2013">{{cite book|author1=Chas Bountra|author2=Rajesh Munglani|author3=William K. Schmidt|title=Pain: Current Understanding, Emerging Therapies, and Novel Approaches to Drug Discovery|url=https://books.google.com/books?id=anRzslvfcUwC&pg=PA567|date=28 May 2013|publisher=CRC Press|isbn=978-0-203-91125-9|pages=567–}}</ref> In addition to its actions at the NMDA receptor, licostinel also acts as an antagonist of the [[AMPA receptor|AMPA]] and [[kainate receptor]]s at high concentrations (K<sub>b</sub> = 0.9 µM and 2.5 µM, respectively).<ref name="pmid8643094" />
